Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology

Grants

Funding Acknowledgements

The following reagent was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), NIH: CEM. NKR-CCR5. We would like to thank (1) the NIAID and the NIAID-funded HVTN for providing specimens for the HVTN204 vaccine trial; (2) the MHRP for specimens from the RV144 vaccine trial; (3) the GSID for samples from the VAX003 vaccine trial; and (4) Dan Barouch for specimens from the experimental Ad26 vaccine trial. We would like to thank the RV144 study team for permission to include the case: control data in our manuscript and would like to specifically thank Drs. Peter Gilbert and Allan DeCamp and Ms. Elizabeth Heger for their assistance in RV144 case: control data collection. The opinions herein are those of the authors and should not be construed as official or representing the views of the U.S. Department of Defense or the Department of the Army. This work was supported by the NIH (grant R01 AI080289); the Bill and Melinda Gates Foundation CAVD (OPP1032817: Leveraging Antibody Effector Function); the Ragon Institute of MGH, MIT and Harvard; and DARPA-BAA-11-65. H. Schuitemaker and M.G.P. are employees of Crucell Holland B.V., a Janssen Pharmaceutical Company of Johnson & Johnson, and shareholders of Johnson & Johnson. H.S. and M.G.P. are employees of Crucell Holland B.V., The Janssen Pharmaceutical Companies of Johnson & Johnson, and shareholders of Johnson & Johnson.